OHSU Knight Cancer Institute Overview and Update

Transcription

1 OHSU Knight Cancer Institute Overview and Update for Senate Health Care and Human Services Committee Steve Stadum, COO, OHSU Knight Cancer Institute September 15, 2014

2 Presentation Brief Overview of OHSU Knight Cancer Institute The Knight Cancer Challenge Partnership with the State of Oregon Fundraising Update $1.2 Billion Plan Benefits for All Oregonians Timeline

3 OHSU s Knight Cancer Institute Highlights NCI-designated Clinical Cancer Center since investigators with over $75 million in peer-reviewed funding Established the paradigm of targeting molecular pathogenetic events in cancer $100 million unrestricted gift from Phil & Penny Knight paid over 7 years, beginning October 2009

4 The Life Cycle of Personalized Cancer Care Survivorship Behavioral Research Psychosocial & Palliative Care Family Needs Health Outcomes Populations at Risk Risk Factors Genetics Early Detection Health Disparities Relapsed Disease Recurrence Therapy Drug Discovery Adaptive Trial Design Intervention Prevention Lifestyle/Nutrition Education Treatment Primary Therapy Multimodality Target Based Post Therapy Surveillance Clinical Trials Matching Prognosis Molecular Oncology Biomarker Analysis Diagnosis Genomics/Proteomics Imaging Modalities Nanotechnology

5 Personalized Medicine: A New Paradigm for Cancer Care Traditional Therapeutic Approaches to Cancer Care High toxicity 50 Cancer Patients Surgery, Chemo and Radiation Therapy Poor prognosis Personalized Medicine: Personalized The New Way Medicine Approach 50 Cancer Patients with Molecular Data RAS-Targeted Therapies ALK-Targeted Therapies EGFR-Targeted Therapies Lower toxicities Better patient outcomes

6 What Did the First Knight Gift Accomplish? Recruitment of >25 new cancer researchers and clinical leaders including: Joe Gray, Ph.D Lisa Coussens, Ph.D. Adam Margolin, Ph.D. Chris Amling, M.D. Sara Courtneidge, Ph.D. Paul Spellman, Ph.D. Pepper Schedin, Ph.D. Sancy Leachman, M.D. Headquarters for NCI s SWOG (national clinical trials organization for community providers) moved to Knight with recruitment of Charles Blanke, M.D. Early adopter of next-generation sequencing/use of cancer panels (Corless/Knight Diagnostic Laboratories)

7 Transformative pledge: The Knight Cancer Challenge On September 21, 2013 Phil and Penny Knight make surprise challenge pledge OHSU will receive $500 million if it raises another half billion by February

8 Partnering with the State of Oregon In February 2014 the State legislature approved $200 million in state bonds to build the infrastructure needed to meet the Knight Cancer Challenge. $200 million from the state will count toward match but will be supplemented after match is met by an additional $200 million in programmatic fundraising to support the $1 billion research program plan

9 Fundraising Progress to Date Total fundraising effort: $1.2 billion investment (program + buildings) Total Commitments as of September 15: $428 million (including $200 million from state for buildings) $72 million needed to trigger $500 million gift from Phil and Penny Knight

10

11 $1.2 Billion Plan $200 million research building and clinical trial building space $250 million endowment $100 million clinical research Faculty recruits, clinical trial infrastructure $550 million molecularly targeted early detection program Biological understanding of transitions to lethal cancer, computational biology, imaging, other detection technologies $100 million Innovation fund, education, statewide community outreach 11

12 OHSU Schnitzer Campus Schnitzer Campus Research Building: Wet Labs Bio-Computing Research Support Parking Zidell Yards (33 acres) CHH CHH 2 OHSU Commons Parking CHHII Patient Care & Clinical Trials: Patient Care Facility Knight Cancer Clinics Knight Cancer Infusion Clinical Trials Parking garage with CUP

13 Why the focus on early detection? Early detection correlates to better patient outcomes Need to replace outdated screening tools Screening is not keeping pace with advances in precision medicine Common tests, mammograms, and PSA are woefully inadequate Unnecessary biopsies, treatments result from imprecise detection Next logical step on a continuum: Targeted molecular therapy molecular early detection molecularly targeted prevention Builds on Knight Cancer Institute s strengths as a pioneering cancer center 13

14 High correlation between late-stage diagnosis and mortality Cancer Type US Incidence (2012) US Mortality (2012) 5-Year Survival % Later Stage Diagnoses (Stages II-IV) 1 Lung & bronchial 228, ,480 17% 79% 2 Colon & rectal 142,820 50,830 65% 56% 3 Breast 234,580 40,030 89% 37% 4 Pancreatic 45,220 38,460 6% 80% 5 Prostate 238,590 29,720 99% 15% 6 Leukemia 48,610 23,720 56% NA* 7 Liver & intrahepatic bile duct 30,640 21,670 16% 45% 8 Lymphoma (Non-Hodgkin s) 69,740 19,020 69% 64% 9 Urinary bladder 72,570 15,210 78% 11% 10 Brain & nervous system 23,130 14,080 34% 18% 11 Ovarian 22,240 14,030 44% 79% Level of Unmet Need: High Medium Low Source: SEER Cancer Statistics, National Cancer Institute November 21,

15 What is molecular early detection? Next-generation detection will identify early warning signals of cancer not currently understood such as intra-cell molecular patterns, the pre-cancerous micro-environment, inflammatory signals, etc. Yet-to-be invented imaging technologies and/or ultra-sensitive tests on blood, saliva or other body fluids capable of reading these signatures Ability to differentiate lethal cancers from abnormalities that do not require treatment 15

16 The Early Detection Plan Assemble the team: Recruit early detection experts to complement existing talent Focus: Liberate top scientists to devote all their time to discovery Provide the tools: Equip the team with state-of-the-art technology Share the knowledge: Distribute information and resources through community and industry partnerships as well as collaborate with other universities Build the pipeline: Train next-generation scientists 16

17 Knight Cancer Challenge Benefits for all Oregonians Recruitment of numerous nationally recognized researchers to the state Establishes world-class infrastructure for basic, translational, and clinical research, including major investments in areas such as computational biology Elevates available cancer treatment Increases number and variety of cancer clinical trials Increases statewide community outreach for cancer prevention and screening Benefits every demographic in the state 17

18 Economic impact from combined $1.2 billion investment During construction phase $892 million in total economic output 6,835 jobs - (FTE for one year) supported directly, indirectly and induced, including 3,605 directly created jobs $35.3 million in tax revenue - $21.3 million in state income tax and $14 million local property tax Ongoing annual impact once fully operational $134 million in total economic output 860 total jobs - supported directly, indirectly, and induced, including about 380 new direct Knight Cancer Institute employees $5.6 million in tax revenue - ($3.4 million state income tax and $2.2 million local property tax) 18

19 Lab-level Multiplier Effect Hiring just one top scientist is like relocating a small research company to Oregon. One Knight recruit recently contributed the following: Relocated 8 junior scientists to the state, each making a sixfigure salaries Hired 45 to run his lab Invested nearly $10 million in research tools Brought in more than 4 million per year in grant funding, industry relationships 19

20 Timeline 2014 February State Legislature approves $200M bonds March 2 year planning process for buildings begins August requests for proposals issued for building design and construction September request for proposals for Community Partnership Program (CPP) grants expected to be issued February first round of CPP grants awarded to communities throughout Oregon Construction planning process continues Recruitment of scientific leaders accelerates 2016 February end of Knight Cancer Challenge March construction begins, state sells bonds 2018 New buildings open on South Waterfront

21 Thank you Questions?